Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 6/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506756 | 0.90 | CCR8 (0.83) | CCR8SIGMAR1 | |
| SCHEMBL6499972 | 0.87 | CCR8 (0.73) | CCR8SIGMAR1CCR3PRKAA2KMT2A | |
| SCHEMBL6498385 | 0.82 | CCR8 (0.82) | CCR8SIGMAR1 | |
| SCHEMBL6501125 | 0.81 | CCR8 (1.00) | CCR8SIGMAR1 | |
| SCHEMBL6496183 | 0.81 | CCR8 (0.80) | CCR8SIGMAR1 | |
| SCHEMBL6499380 | 0.80 | CCR8 (1.00) | CCR8SIGMAR1CCR3 | |
| SCHEMBL6499968 | 0.80 | CCR8 (0.78) | CCR8SIGMAR1 | |
| SCHEMBL6507394 | 0.79 | CCR8 (0.78) | CCR8SIGMAR1CCR3PRKAA2KMT2A | |
| SCHEMBL6500103 | 0.79 | CCR8 (1.00) | CCR8SIGMAR1POLBKDM4EALDH1A1 | |
| SCHEMBL6507695 | 0.79 | CCR8 (0.75) | CCR8SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885SIGMAR1 525/4885CCR3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.